Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile

References

• GINA main report - Global Initiative for Asthma; 2021. Available from: https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Accessed June 11, 2021.
   Google Scholar
• Rogliani P, Ritondo BL, Facciolo F, Matera MG, Nikolaev I, Calzetta L. Indacaterol, glycopyrronium, and mometasone: pharmacological interaction and anti-inflammatory profile in hyperresponsive airways. Pharmacol Res. 2021;172:105801. doi:10.1016/J.PHRS.2021.105801
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ritondo BL, Calzetta L. Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. Eur Respir J. 2021;58(3):2004233. doi:10.1183/13993003.04233-2020
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L. Clinical Interpretation of efficacy outcomes in pharmacological studies on triple fixed-dose combination therapy for uncontrolled asthma: assessment of IRIDIUM and ARGON studies. J Exp Pharmacol. 2022;14:1–5. doi:10.2147/JEP.S336304
   PubMedGoogle Scholar
• Scosyrev E, van Zyl-smit R, Kerstjens H, et al. Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of Phase 3 trials. Respir Med. 2021;180:106311. doi:10.1016/j.rmed.2021.106311
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1. doi:10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Schardt C, Adams MB, Owens T, Keitz S, Fontelo P. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inf Decis Mak. 2007;7(1):16. doi:10.1186/1472-6947-7-16
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. doi:10.1016/0197-2456(95)00134-4
   PubMedGoogle Scholar
• Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394. doi:10.1016/j.jclinepi.2010.04.026
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Available from: https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Accessed April 19, 2021.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Inhaled corticosteroid doses for NICE’s asthma guideline; 2018. Available from: www.nice.org.uk/guidance/ng80/resources/inhaled-corticosteroid-doses-pdf-4731528781. Accessed January 16, 2020.
   Google Scholar
• Pedder H, Sarri G, Keeney E, Nunes V, Dias S. Data extraction for complex meta-analysis (DECiMAL) guide. Syst Rev. 2016;5(1):212. doi:10.1186/s13643-016-0368-4
   PubMedGoogle Scholar
• Gianinazzi ME, Rueegg CS, Zimmerman K, Kuehni CE, Michel G; Swiss Paediatric Oncology G. Intra-rater and inter-rater reliability of a medical record abstraction study on transition of care after childhood cancer. PLoS One. 2015;10(5):e0124290. doi:10.1371/journal.pone.0124290
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Section 4.8 Undesirable effects. Available from https://www.ema.europa.eu/en/documents/presentation/presentation-section-48-undesirable-effects_en.pdf. Accessed April 20, 2022.
   Google Scholar
• Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: assessing risk of bias in a randomized trial. In: Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (Updated July 2019). Cochrane, 2019; 2019:205–228. Available from www.training.cochrane.org/handbook.
   Google Scholar
• Wallace BC, Dahabreh IJ, Trikalinos TA, Lau J, Trow P, Schmid CH. Closing the gap between methodologists and end-users: r as a computational back-end. J Stat Softw. 2012;49(5):1–15. doi:10.18637/jss.v049.i05
   Web of Science ®Google Scholar
• Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.557
   PubMed Web of Science ®Google Scholar
• Sankey SS, Weissfeld LA, Fine MJ, Kapoor W. An assessment of the use of the continuity correction for sparse data in meta-analysis. Commun Stat Part B Simul Comput. 1996;25(4):1031–1056. doi:10.1080/03610919608813357
   Web of Science ®Google Scholar
• Sterne JAC, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119–1129. doi:10.1016/S0895-4356(00)00242-0
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54(10):1046–1055. doi:10.1016/S0895-4356(01)00377-8
   PubMed Web of Science ®Google Scholar
• Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.629
   PubMed Web of Science ®Google Scholar
• 10.4.3.1 Recommendations on testing for funnel plot asymmetry. Available from: https://handbook-5-1.cochrane.org/chapter_10/10_4_3_1_recommendations_on_testing_for_funnel_plot_asymmetry.htm. Accessed January 2, 2022.
   Google Scholar
• Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• McGuinness LA. robvis: an R package and web application for visualising risk-of-bias assessments; 2020.
   Google Scholar
• Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69–84. doi:10.1016/S2213-2600(20)30389-1
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000–1012. doi:10.1016/S2213-2600(20)30190-9
   PubMed Web of Science ®Google Scholar
• Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749. doi:10.1016/S0140-6736(19)32215-9
   PubMed Web of Science ®Google Scholar
• Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26(1):53–77. doi:10.1002/SIM.2528
   PubMed Web of Science ®Google Scholar
• 16.9.5 Validity of methods of meta-analysis for rare events. Available from: https://handbook-5-1.cochrane.org/chapter_16/16_9_5_validity_of_methods_of_meta_analysis_for_rare_events.htm. Accessed January 10, 2022.
   Google Scholar
• Usmani OS. Small-airway disease in asthma: pharmacological Considerations. Curr Opin Pulm Med. 2015;21(1):55–67. doi:10.1097/MCP.0000000000000115
   PubMed Web of Science ®Google Scholar
• Canonica GW, Ferrando M, Baiardini I, et al. Asthma: personalized and precision medicine. Curr Opin Allergy Clin Immunol. 2018;18(1):51–58. doi:10.1097/ACI.0000000000000416
   PubMed Web of Science ®Google Scholar
• Heffler E, Canonica GW, Diamant Z, Fonseca J, Malinovschi A. Personalized approach to severe asthma. Biomed Res Int. 2018;2018:1–2. doi:10.1155/2018/2465172
   Web of Science ®Google Scholar
• Calzetta L, Puxeddu E, Rogliani P. Gender-related responsiveness to the pharmacological treatment of COPD: a first step towards the personalized medicine. EBioMedicine. 2017;19:14–15. doi:10.1016/j.ebiom.2017.04.035
   PubMed Web of Science ®Google Scholar
• Ora J, Coppola A, Cazzola M, Calzetta L, Rogliani P. Long-acting muscarinic antagonists under investigational to treat chronic obstructive pulmonary disease. J Exp Pharmacol. 2020;12:559–574. doi:10.2147/JEP.S259330
   PubMedGoogle Scholar
• Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003;112(3):S1–S40. doi:10.1016/S0091-6749(03)01859-1
   PubMedGoogle Scholar
• European Medicine Agency. Refusal of change to the marketing authorisation for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol). Available from: https://www.ema.europa.eu/en/documents/smop/questions-answers-refusal-change-marketing-authorisation-trelegy-ellipta-fluticasone-furoate/umeclidinium/vilanterol_en.pdf. Accessed April 20, 2022.
   Google Scholar